Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;47(2):133-42.
doi: 10.1053/j.seminhematol.2010.01.003.

Rituximab in indolent lymphomas

Tarek Sousou  1 , Jonathan Friedberg
Affiliations
Review

Rituximab in indolent lymphomas

Tarek Sousou et al. Semin Hematol. 2010 Apr.

Abstract

Indolent non-Hodgkin lymphoma (NHL) comprises a group of incurable, generally slow-growing lymphomas highly responsive to initial therapy, with a relapsing and progressive course. Rituximab, an anti-CD20 antibody, has had a large impact on the treatment of indolent NHL. Its effectiveness as a single agent and in conjunction with known chemotherapy regimens has made it a standard of care in the treatment of NHL. Analysis of data obtained from NHL clinical trials, as well as data from the National Cancer Institute, indicate that the overall survival (OS) of patients with indolent NHL has improved since the discovery of rituximab. Given its effectiveness and tolerability, rituximab is currently being investigated as a maintenance agent with encouraging results. This review summarizes several landmark trials utilizing rituximab as a single agent and in combination with chemotherapy for treatment of NHL. In addition, a review of the studied rituximab maintenance dosing schedules and its impact on NHL will be presented. Overall, rituximab has changed the landscape for treatment of indolent NHL; however, additional research is necessary to identify the optimal dosing schedule, as well as patients most likely to respond to prolonged rituximab therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival according to chemotherapy regimen: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MoAb, monoclonal antibody; ProMACE, prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide. Reprinted with permission.
Figure 2
Figure 2
Progression-free survival in those randomized to maintenance rituximab versus retreatment at time of progression. Reprinted with permission.
Figure 3
Figure 3
Duration of response to rituximab treatment according to maintenance or re-treatment at time of progression. Reprinted with permission.
See this image and copyright information in PMC

References

    1. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362:516–522. - PubMed
    1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Seminars in oncology. 1993;20:75–88. - PubMed
    1. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995;13:140–147. - PubMed
    1. Montoto S, López-Guillermo A, Ferrer A, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2002;13:523–530. - PubMed
    1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909–3918. - PubMed

MeSH terms